1. Signaling Pathways
  2. Immunology/Inflammation
  3. CTLA-4


Cytotoxic T-lymphocyte-associated protein 4; CD152

Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), also known as CD152, is an inhibitory receptor belonging to the CD28 immunoglobulin subfamily. CTLA-4 is expressed primarily by T cells. The ligands of CTLA-4, CD80 and CD86, are typically found on the surface of antigen-presenting cells and can either bind CD28 or CTLA-4. The interactions of the ligands with CTLA-4 serve to inhibit T cell responses. Because of its dampening effect, CTLA-4 is a crucial regulator of T-cell homeostasis and self-tolerance. The mechanisms by which CTLA-4 exerts its inhibitory function can be categorized as either cell-intrinsic (affects the CTLA-4 expressing T-cell) or cell-extrinsic (affects secondary cells). CTLA-4 is well recognized as a key immune checkpoint and has gained significant momentum as a therapeutic target in the field of autoimmunity and cancer.

目录号 产品名 作用方式 纯度
  • HY-P9901


    Ipilimumab 是一种全人类单克隆抗体 IgG1κ,能够抗 CTLA-4(一种由活化的 T 细胞产生的免疫抑制分子)。
  • HY-108829
    Abatacept ≥99.0%
    Abatacept (CTLA4lg) 是一种可溶性融合蛋白,由人 CTLA4 的胞外结构域和人 IgG1 Fc 部分的片段 (铰链,CH2 和 3 结构域) 组成。Abatacept 是选择性 T 细胞共刺激调节剂,也是一种用于自身免疫性疾病的蛋白药物。
  • HY-P99166
    Vudalimab Inhibitor
    Vudalimab 是一种有效的 PD-1CTLA-4 双重抑制剂,是一种完全人源化的双特异性单克隆抗体。Vudalimab 靶向免疫检查点受体 PD-1 和 CTLA-4,促进肿瘤选择性 T 细胞激活。
目录号 产品名 / 同用名 种属 表达系统